KEGG   DRUG: Inclisiran
Entry
D11931                      Drug                                   
Name
Inclisiran (USAN/INN);
Leqvio (TN)
Formula
C529H707F12N176O316P43S6
Exact mass
16331.1514
Mol weight
16339.5061
Class
Hypolipidemic agent
 DG01946  Hypolipidemic agent
  DG03128  Anti-PCSK9 antibody and siRNA
Remark
ATC code: C10AX16
Chemical structure group: DG03216
Product (DG03216): D12293<JP/US>
Efficacy
Antihyperlipidemic, Translation inhibitor
  Disease
Heterozygous familial hypercholesterolemia [DS:H00155]
Atherosclerotic cardiovascular disease [DS:H02505]
  Type
RNA interference (RNAi) drug
Comment
Treatment of hypercholesterolemia
Target
PCSK9 [HSA:255738] [KO:K13050]
  Pathway
hsa04979  Cholesterol metabolism
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C10 LIPID MODIFYING AGENTS
   C10A LIPID MODIFYING AGENTS, PLAIN
    C10AX Other lipid modifying agents
     C10AX16 Inclisiran
      D11931  Inclisiran (USAN/INN)
Drug groups [BR:br08330]
 Hypolipidemic agent
  DG01946  Hypolipidemic agent
   DG03128  Anti-PCSK9 antibody and siRNA
    DG03216  Inclisiran
     D11931  Inclisiran
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Serine peptidases
    PCSK9
     D11931  Inclisiran (USAN/INN)
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11931
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11931
Drug groups [BR:br08330]
 Hypolipidemic agent
  DG01946  Hypolipidemic agent
   DG03128  Anti-PCSK9 antibody and siRNA
    DG03216  Inclisiran
Other DBs
CAS: 1639324-58-5
ChEBI: 176399
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system